Would legalizing illicit opioids reduce overdose fatalities? Implications from a natural experiment

Addiction

Volumn 109, Issue 8, 2014, Pages 1237-1242

  Darke, Shane ^a   Farrell, Michael ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Heroin; Legalization; Mortality; Opioids; Overdose; Oxycodone

Indexed keywords

STREET DRUG;

COMPLICATION; DRUG OVERDOSE; HEROIN DEPENDENCE; HUMAN; INTERNATIONAL COOPERATION; LEGISLATION AND JURISPRUDENCE; OPIATE ADDICTION;

DRUG OVERDOSE; HEROIN DEPENDENCE; HUMANS; INTERNATIONALITY; OPIOID-RELATED DISORDERS; STREET DRUGS;

EID: 84904008910     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12456     Document Type: Article

References (64)

1. Bauer S. M., Loiple R., Jagsch R., Gruber D., Risser D., Tahu K. etal. Mortality in opioid-maintained patients after release from an addiction clinic. Eur Addict Res 2008; 14: 82-91.
2. Bird S. M. Over 1200 drugs-related deaths and 190, 000 opiate-users-years of follow-up: relative risks by sex and age group. Addict Res Theory 2010; 18: 194-207.
3. Darke S. The Life of the Heroin User: Typical Beginnings, Trajectories and Outcomes. Cambridge: Cambridge University Press; 2011.
4. Darke S., Mills K. L., Ross J., Teesson M. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. Drug Alcohol Depend 2011; 115: 190-195.
5. Degenhardt L., Bucello C., Mathers B., Briegleb C., Ali H., Hickman M. etal. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
6. Stenbacka M., Liefman L., Romelsjo A. Mortality and cause of death among 1705 illicit drug users, a 37 year follow-up. Drug Alcohol Rev 2010; 29: 21-27.
7. Bargagli A. M., Hickman M., Davoli M., Perucci C. A., Schifano P., Buster M. etal. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006; 16: 198-202.
8. Soyka M., Apelt S., Lieb M., Wittchen H. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006; 26: 657-660.
9. Karch S. B. Karch's Pathology of Drug Abuse, 4th edn. Boca Raton, FL: CRC Press; 2009.
10. Backmunda M., Schuetzb C., Meyera K., Edlinc B. R., Reimer J. The risk of emergency room treatment due to overdose in injection drug users. J Addict Dis 2009; 28: 68-73.
11. Bargagli A. M., Faggiano F., Amato L., Salamina G., Davoli M., Mathis F. etal. VEdeTTE, a longitudinal study on effectiveness of treatments for heroin addiction in Italy: study protocol and characteristics of study population. Subst Use Misuse 2006; 41: 1861-1879.
12. Britton P. C., Wines J. D., Conner K. R. Non-fatal overdose in the 12 months following treatment for substance use disorders. Drug Alcohol Depend 2010; 107: 51-55.
13. Darke S., Ross J., Williamson A., Mills K. L., Havard A., Teesson M. Patterns of non-fatal heroin overdose over a three year period: findings from the Australian Treatment Outcome Study. J Urban Health 2007; 84: 283-291.
14. Kerr T., Fairbairn N., Tyndall M., Marsh D., Li K., Montaner J. etal. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend 2007; 87: 39-45.
15. Wines J. D., Saitz R., Horton N. J., Lloyd-Travaglini C., Samet J. H. Overdose after detoxification: a prospective study. Drug Alcohol Depend 2007; 89: 161-169.
16. Darke S., Mattick R., Degenhardt L. The ratio of non-fatal to fatal overdose. Addiction 2003; 98: 1169-1170.
17. Maxwell J. C. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev 2011; 30: 264-270.
18. Rehm J., Frick U., Hartwig C., Gutzwiller F., Gschwend P., Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994-2000. Drug Alcohol Depend 2005; 79: 137-143.
19. Strang J., Metrebian N., Lintzeris N., Potts L., Carnwath T., Mayet S. etal. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375: 1885-1895.
20. Burrows D. Towards a regulated market for illicit drugs: effects of the harm reduction model of controlled drug availability. Int J Drug Policy 2005; 16: 8-9.
21. Edwards G. Matters of Substance. Drugs: Is Legalisation the Right Answer-or the Wrong Question? London: Allen Lane 2005.
22. MacCoun R. J. Assessing drug prohibition and its alternatives: a guide for agonistics. Annu Rev Law Soc Sci 2011; 7: 61-78.
23. MacCoun R. J., Reuter P. Drug War Heresies. Learning from Other Vices, Times and Places. Cambridge: Cambridge University Press; 2001.
24. Darke S. Polydrug use and overdose: overthrowing old myths. Addiction 2003; 98: 711.
25. Darke S., Duflou J., Torok M. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend 2010; 106: 1-6.
26. Bryant W. K., Galea S., Tracy M., Piper T. M., Tardiff K. J., Vlahov D. Overdose deaths attributed to methadone and heroin in New York City, 1990-1998. Addiction 2003; 99: 846-854.
27. Davidson P. J., McLean R. L., Kral A. H., Gleghorn A. A., Edlin B. R., Moss A. R. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health 2003; 80: 261-273.
28. Brescher E. M. The 'heroin overdose' mystery and other hazards of addiction. In: Brescher E. M., editor, the Editors of Consumer Reports. In: Licit and Illicit Drugs: The Consumer Union Report on Narcotics, Stimulants, Depressants, Inhalants, Hallucinogens and Marijuana-Including Caffeine, Nicotine and Alcohol. Boston, MA: Little & Brown; 1972, pp. 101-114.
29. Aderjan R., Hoemann S., Schmitt G., Skopp G. Morphine and morphine glucuronides in serum of heroin consumers and in heroin-related deaths determined by HPLC with native fluorescence detection. J Anal Toxicol 1995; 19: 163-168.
30. Darke S., Duflou J., Kaye S. Comparative toxicology of fatal heroin overdose cases and morphine positive homicide victims. Addiction 2007; 102: 1793-1797.
31. Darke S., Sunjic S., Zador D., Prolov T. A comparison of blood toxicology of heroin related deaths and current users in Sydney, Australia. Drug Alcohol Depend 1997; 47: 45-53.
32. Monforte J. R. Some observations concerning blood morphine concentrations in narcotic addicts. J Forensic Sci 1977; 22: 718-724.
33. Desmond D. P., Maddux J. F., Trevino A. Street heroin potency and deaths from overdose in San Antonio. Am J Drug Alcohol Abuse 1978; 5: 39-49.
34. Ruttenber A. J., Luke J. L. Heroin-related deaths: new epidemiologic insights. Science 1984; 226: 14-20.
35. Darke S., Hall W., Weatherburn D., Lind B. Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug Alcohol Depend 1999; 54: 155-161.
36. Risser D., Uhl A., Stichenwirth M., Honigschnabl S., Hirz W., Schneider B. etal. Quality of heroin and heroin-related deaths from 1987 to 1995 in Vienna, Austria. Addiction 2000; 95: 375-382.
37. Darke S., Ross J., Hall W. Overdose among heroin users in Sydney, Australia I. Prevalence and correlates of non-fatal overdose. Addiction 1996; 91: 405-411.
38. Darke S., Ross J., Zador D., Sunjic S. Heroin-related deaths in New South Wales, Australia, 1992-1996. Drug Alcohol Depend 2000; 60: 141-150.
39. Ruttenber A. J., Kalter H. O., Santinga P. The role of ethanol abuse in the etiology of heroin-related death. J Forensic Sci 1990; 35: 891-900.
40. Coffin P. O., Galea S., Ahern J., Leon A. C., Vlahov D., Tardiff K. Opiate, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-1998. Addiction 2003; 98: 739-747.
41. Auriacombe M., Franque P., Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285: 45.
42. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121: 65-69.
43. Gagajewski A., Apple F. S. Methadone-related deaths in Hennepin County, Minnesota, 1992-2002. J Forensic Sci 2003; 48: 668-671.
44. Merrall E. L. C., Kariminia A., Binswanger I. A., Hobbs M. S., Farrell M., Marsden J. etal. Meta-analysis of drug-related deaths soon after release from prison. Addiction 2010; 105: 1545-1554.
45. Strang J., McCambridge J., Best D., Beswick T., Bearn J., Rees S. etal. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 356: 959-960.
46. Tagliaro F., Debattisti Z., Smith F. P., Marigo M. Death from heroin overdose: findings from hair analysis. Lancet 1998; 351: 1923-1925.
47. Teesson M., Havard A., Ross J., Darke S. Outcomes after detoxification for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev 2006; 25: 241-247.
48. Bohnert A. S. B., Valenstein M., Bair M. J., Ganoczy D., McCarthy J. F., Ilgen M. A. etal. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315-1321.
49. Carise D., Dugosh K. L., McLellan A. T., Camilleri A., Woody G. E., Lynch K. G. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 2007; 164: 1750-1756.
50. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. Morb Mortal Wkly Rep 2011; 60: 1-6.
51. Centers for Disease Control and Prevention. CDC Grand Rounds: prescription drug overdoses-a U.S. epidemic. Morb Mortal Wkly Rep 2012; 61: 10-13.
52. Cone E. J., Fant R. V., Rohay J. M., Caplan Y. H., Ballina M., Reder R. F. etal. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol 2004; 28: 217-5.
53. Darke S., Duflou J., Torok M. Toxicology and characteristics of fatal oxycodone toxicity cases in New South Wales, Australia 1999-2008. J Forensic Sci 2011; 56: 690-693.
54. Dhalla I. A., Mamdani M. M., Sivilotti M. L. A., Kopp A., Qureshi O., Juurlink D. N. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Can Med Assoc J 2009; 181: 891-896.
55. Hall A. J., Logan J. E., Toblin R. L., Kaplan J. A., Kraner J. C., Bixler D. etal. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300: 2613-2620.
56. Ogle A., Moore K., Barrett B., Young M. S., Pearson J. Clinical history and characteristics of persons with oxycodone-related deaths in Hillsborough County, Florida in 2009. Forensic Sci Int 2012; 223: 47-52.
57. Paulozzi L. J., Ryan G. W. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006; 31: 506-511.
58. Rintoul A. C., Dobbin M. D. H., Drummer O. H., Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2011; 17: 254-259.
59. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. NSDUH Series H-38A. Rockville, MD: Office of Applied Studies; 2010.
60. Wolf B. C., Lavezzi W. A., Sullivan L. M., Flannagan L. M. One hundred seventy two deaths involving the use of oxycodone in Palm Beach County. J Forensic Sci 2005; 50: 192-195.
61. Darke S., Ross J., Mills K. L., Williamson A., Havard A., Teesson M. Injecting and non-injecting heroin administration: transitions and treatment outcomes across 36 months. J Drug Issues 2008; 38: 543-558.
62. Neaigus A., Gyermathy A., Miller M., Frajzngier V. M., Friedman S. R., Des Jarlais D. C. Transitions to injecting drug use amongst noninjecting heroin users. J Acquir Immune Defic Syndr 2006; 41: 493-503.
63. Darke S., Hall W., Kaye S., Ross J., Duflou J. Hair morphine concentrations of fatal heroin overdose cases and living heroin users. Addiction 2002; 97: 977-984.
64. Farrell M., Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 2007; 103: 251-255.